去纤苷有哪些副作用？

Side effects of defibrotide include hypotension, diarrhea, vomiting, nausea, epistaxis, and allergic reactions, including rash, angioedema, and urticaria.

If the patient develops bleeding symptoms during treatment, the medication should be stopped and treated under the guidance of a doctor until the bleeding stops.

Hepatic veno-occlusive disease (VOD), also known as sinusoidal veno-occlusive syndrome (SOS), is the most common complication in patients in the early postoperative period after hematopoietic stem cell transplantation (HSCT). In severe cases, VOD/SOS may be associated with multi-organ failure and has a mortality rate of 80% within 100 days.

Defibrotide has been proposed for the treatment of SOS due to its ability to restore the thrombo-fibrinolytic balance and protect endothelial cells. Studies have shown that defibrotide shows good efficacy in treating liver VOD/SOS.

One study examined the safety and efficacy of defibrotide in patients with established hepatic VOD/SOS and advanced MOF. Through 32 historical controls, patients taking defibrotide 25 mg/kg daily were compared, and the baseline characteristics were well balanced between the groups.

The primary endpoint is survival at 100 days after hsct. The observation rate was 38.2% in the defibrotide group and 25% in the control group. The observed 100-day complete remission (CR) rate was 25.5% in the defibrotide group and 12.5% ​​in the control group.

Defibrotide is generally well tolerated and its toxicity is controllable. Relevant adverse events (AEs) included bleeding or hypotension, and common hemorrhagic AEs (including alveolar hemorrhage and gastrointestinal bleeding) occurred at similar rates between the defibrinoside and control groups, respectively.

It can be seen that defibrotide can significantly improve the 100-day survival rate and CR rate of patients.

Things to note

It should be noted that it is contraindicated by people who are allergic to defibrotide ingredients. Defibrinoside and systemic anticoagulation or fibrinolytic therapy may increase the risk of bleeding, so this drug should not be used in combination with systemic anticoagulation or fibrinolytic therapy. In addition, the drug must be diluted before use and cannot be infused intravenously with other drugs.

Recommended related articles: